Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead's (GILD) HCV Drug Application Accepted in the EU

Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

    AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

    AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

      Stock Market News for June 23, 2017

      The Nasdaq finished in the green for consecutive sessions on Thursday, boosted primarily by gain in health care shares

        Tracey Ryniec headshot

        How to Find the Best Value Stocks

        A great value stock isn't just a cheap stock. Tracey uses a "secret sauce" to find the hidden gems among the cheap stocks.

          Arpita Dutt headshot

          Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

          Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

            Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

            Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

              Is Gilead Sciences a Great Stock for Value Investors?

              Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

                Epizyme Provides Positive Interim Data on EZH2 Inhibitor

                Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

                  Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

                    Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen

                    Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.

                      The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife

                      The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife

                        Sheraz Mian headshot

                        Top Stock Reports for Gilead, BP & Dow Chemical

                        Today's Research Daily features new research reports on 17 major stocks, including Gilead (GILD), BP (BP), and Dow Chemical (DOW).

                          Why Is Gilead Sciences (GILD) Down 3.5% Since the Last Earnings Report?

                          Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Gilead Single Tablet Regiment for HIV Good in Phase III

                            Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.

                              Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose

                              Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.

                                Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada

                                Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.

                                  Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose

                                  Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.

                                    Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron

                                    Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron

                                      Tracey Ryniec headshot

                                      Value Stock or Value Trap?

                                      Tracey tells you how not to get fooled by value trap stocks on this week's podcast.

                                        The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric

                                        The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric

                                          Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat

                                          Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.

                                            Mark Vickery headshot

                                            Top Research Reports for Today: GILD, DOW, MET & More

                                            Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Dow Chemical (DOW) and MetLife (MET).

                                              Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus

                                              Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.

                                                Madeleine Johnson headshot

                                                After Gilead Earnings, Buy These Biotech Stocks

                                                Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.

                                                  Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

                                                  Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.